HC Wainwright Issues Pessimistic Estimate for ORKA Earnings

Oruka Therapeutics, Inc. (NASDAQ:ORKA) – HC Wainwright decreased their FY2024 earnings estimates for shares of Oruka Therapeutics in a report issued on Monday, November 25th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of ($2.24) for the year, down from their previous estimate of ($1.56). HC Wainwright has a “Buy” rating and a $45.00 price objective on the stock. The consensus estimate for Oruka Therapeutics’ current full-year earnings is ($3.10) per share. HC Wainwright also issued estimates for Oruka Therapeutics’ Q4 2024 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.52) EPS and FY2025 earnings at ($1.98) EPS.

A number of other analysts have also commented on the stock. Lifesci Capital began coverage on shares of Oruka Therapeutics in a research note on Monday, September 16th. They set an “outperform” rating and a $41.00 price objective for the company. Stifel Nicolaus began coverage on Oruka Therapeutics in a research report on Friday, October 11th. They set a “buy” rating and a $49.00 price objective for the company. TD Cowen initiated coverage on shares of Oruka Therapeutics in a research report on Monday, September 16th. They issued a “buy” rating for the company. Jefferies Financial Group began coverage on shares of Oruka Therapeutics in a research report on Friday, September 13th. They set a “buy” rating and a $40.00 price objective on the stock. Finally, Wedbush reiterated an “outperform” rating and issued a $40.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, November 19th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Oruka Therapeutics has an average rating of “Buy” and an average price target of $43.17.

Oruka Therapeutics Stock Performance

Oruka Therapeutics stock opened at $20.26 on Wednesday. The business has a 50 day simple moving average of $25.67. The firm has a market capitalization of $709.08 million, a price-to-earnings ratio of -3.24 and a beta of 0.87. Oruka Therapeutics has a 1 year low of $18.20 and a 1 year high of $53.88.

Institutional Trading of Oruka Therapeutics

Several large investors have recently added to or reduced their stakes in ORKA. Great Point Partners LLC acquired a new stake in shares of Oruka Therapeutics in the 3rd quarter valued at $12,614,000. Geode Capital Management LLC bought a new stake in Oruka Therapeutics during the third quarter worth approximately $343,000. Franklin Resources Inc. acquired a new position in Oruka Therapeutics during the third quarter valued at approximately $17,661,000. Wellington Management Group LLP bought a new position in shares of Oruka Therapeutics in the third quarter valued at approximately $2,013,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Oruka Therapeutics in the third quarter worth $1,037,000. 56.44% of the stock is owned by institutional investors.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.